INTRODUCTION
The 13 C-urea breath test ( 13 C-UBT) is a technically simple and non-invasive test for the diagnosis of Helicobacter pylori infection. The accuracy of 13 C-UBT in the diagnosis of H. pylori infection is high, with a sensitivity of 90-98% and a specificity of 92-100%. [1] [2] [3] [4] [5] [6] The sensitivity and specificity of post-treatment 13 C-UBT are as high as those of pre-treatment 13 C-UBT, making it a reliable test for the determination of post-treatment H. pylori status. 7 Since the first description of 13 C-UBT by Graham et al., 8 several modifications have been published to simplify and optimize the test, including the amount of 13 C-urea used, type of test meal, number of samples and sampling time. Citrate has been described to be the best test meal. 9, 10 Previously, we have shown that a 50-mg 13 C-UBT protocol with or without citrate, using a sampling point at 20 min, is an accurate and cost-saving approach for the diagnosis of H. pylori infection in the Chinese population. 11 Recently, a newly developed rapid-release tablet containing 13 C-urea and citric acid has been described. 12 By enclosing the 13 C-urea in a capsule, contamination by urease-producing oropharyngeal bacteria is avoided. This protocol has been investigated in a European population, with a sensitivity of 95% and a specificity of 100%. 12 However, the dose of 13 C-urea used was 100 mg (two tablets), 12 which increased the cost of the test. On the basis of our previous experience with the 50-mg 13 C-UBT protocol (powder), we postulate that this novel 13 C-urea tablet at a dose of 50 mg may be equally reliable for the diagnosis of H. pylori infection.
Thus, the aims of this study were: (i) to investigate the 50-mg 13 C-urea tablet protocol and determine the optimal cut-off value; (ii) to determine the optimal measurement interval of this protocol; and (iii) to investigate whether the accuracy of this protocol can be maintained in patients post-eradication.
METHODS

Patient population
Patients referred to the endoscopy unit of the Department of Medicine, Queen Mary Hospital, Hong Kong for the investigation of dyspepsia or for follow-up after H. pylori eradication and ⁄ or ulcer healing were recruited. Dyspepsia was defined as persistent or recurrent upper abdominal pain or discomfort over the preceding 3-month period. Informed written consent was obtained from all patients participating in the trial. Exclusion criteria included patients with previous gastric surgery and patients taking antibiotics, H 2 -receptor antagonists, bismuth compounds or proton pump inhibitors in the 4 weeks before endoscopy. Patients with a past history of H. pylori eradication were allowed to enter the study provided that the medication for eradication had been stopped for at least 4 weeks and the other inclusion and exclusion criteria were met.
Gastric biopsies
During upper endoscopy, two antral biopsies and one corpus biopsy were taken. One antral biopsy was used for rapid urease test and the rest were sent for histological examination of H. pylori status by haematoxylin and eosin staining and modified Giemsa staining if necessary. For patients who had received eradication therapy within the past 3 months, an additional body biopsy was obtained for rapid urease test. The definition of H. pylori infection required both rapid urease test and histology to be positive and was used as the Ôgold standardÕ in this study. Equivocal cases were excluded from the analysis. This approach has been validated previously in our centre, with a sensitivity and specificity of 100%, and less than 1% of cases cannot be diagnosed by this method. 
Statistical analysis
The statistics used included Student's t-test, the chisquared test and Fisher's exact test when appropriate. A P value of 0.05 or less was considered to be statistically significant.
RESULTS
Two hundred and nine patients were recruited. Nine cases were excluded from the analysis. Four cases had incomplete breath test data and five cases could not be classified according to our gold standard for the diagnosis of H. pylori infection, i.e. only one positive test out of the two tests (histology and rapid urease test). Thus, a total of 200 patients were available for analysis. Of these 200 patients, 50 had received eradication therapy within 3 months before the breath test, i.e. post-eradication patients. The mean age of the 200 patients was 48.4 years (range, 18-86 years). There were 87 males and 113 females. Ninety-nine per cent of the study patients were ethnic Chinese. Ninety-nine patients (50%) were diagnosed as H. pylori positive by the gold standard, 20 of which were post-eradication patients. Only one of the 20 H. pylori-positive posteradication patients had a discordant rapid urease test between the antrum and the corpus (antral negative but corpus positive). Of these 99 H. pylori-positive patients, three had gastric ulcer (3%), 17 had duodenal ulcer (17%), one had gastric and duodenal ulcers (1%), 17 had gastro-duodenal erosions (17%) and one had oesophagitis (1%). One hundred and one patients (50%) were H. pylori negative by our gold standard. Of these 101 patients, two had duodenal ulcer (2%), one had gastric ulcer (1%), six had gastro-duodenal erosions (6%), one had gastric polyp (1%) and five had oesophagitis (5%). H. pylori status correlated strongly with the presence of duodenal ulcers (P < 0.001) and gastro-duodenal erosions (P ¼ 0.006).
The calculated cut-off values were 1.2&, 2.1& and 1.2& for the 10-min, 20-min and 30-min measurement points, respectively ( Table 1 ). The sensitivity, specificity and accuracy of the 50-mg tablet-based 13 C-UBT at 10, 20 and 30 min were 100%, 98% and 99%, 100%, 100% and 100%, and 100%, 98% and 99%, respectively. The 13 C-urea tablet was easy to swallow and well tolerated by all patients. There was no difference in accuracy between patients before eradication therapy and those after eradication therapy (data not shown). The reading at the 10-min sampling point was greater than that at 30 min (25.4 vs. 20.6, P ¼ 0.14), after H. pylori eradication, but the P value was insignificant.
However, the small number of patients (n ¼ 20) in this particular subgroup may limit the power to detect a difference between the 10-min and 30-min measurements. For H. pylori-negative patients, the mean excess d 13 CO 2 excretion was less than 0.3 at all three sampling points irrespective of eradication status (Table 1 , Figure 1 ). Five patients could not be classified according to our gold standard of H. pylori infection due to discordant results between rapid urease test and histology. Two patients had received eradication therapy previously. All five patients were invited to repeat a standard 13 C-UBT using a validated 75-mg 13 C-urea protocol. 6 There was total agreement between the 50-mg tabletbased 13 C-UBT and the conventional 75-mg 13 C-UBT, suggesting that the discrepant results were due to the inaccuracy of the biopsy-based tests (Table 2) . meal has been validated in the Chinese population previously, with a sensitivity and specificity of 100% and 98%, respectively, using a cut-off of 3& and a Figure 1 . Mean delta over baseline (DOB) ± S.E.M. in Helicobacter pylori-positive and H. pylori-negative patients at 10-, 20-and 30-min sampling points (before, before eradication; after, after eradication). ***P < 0.001 when compared with the mean DOB at 30 min in patients before eradication. **P < 0.01 when compared with the mean DOB at 30 min in patients after eradication. *P ¼ 0.73 when compared with the mean DOB at 10 min before eradication.
50-MG TABLET-BASED 1 3 C-UREA BREATH TEST 255 measurement interval of 20 min. 11 The calculated cutoff values of the novel 50-mg Diabact UBT were 1.2&, 2.1& and 1.2& for the 10-min, 20-min and 30-min measurement points, respectively. The sensitivity and specificity of the 50-mg Diabact UBT were 100% and 98%, 100% and 100%, and 100% and 98% at 10 min, 20 min and 30 min, respectively. The accuracy of this protocol is preserved in post-eradication patients.
At present, there is universal agreement that two samples should be taken: a baseline sample collected at time zero and a 30-min sample collected after the ingestion of 13 C-urea. 13 C is measured as the 13 CO 2 :
12 CO 2 isotope ratio and is expressed as the excess d 13 CO 2 excretion. The cut-offs in the three measurement intervals were determined by three standard deviations above the mean excess d 13 CO 2 excretion of H. pylori-negative patients. The cut-off determined by this method correlated well with that of Hamlet et al.
12
The major advance of this novel 50-mg Diabact UBT is that it has an almost instantaneous disintegration and dissolution after entering the stomach. 12 This rapid-release formulation is supported by the fact that the mean excess d 13 CO 2 excretion peaked at the 10-min and 20-min sampling points. For H. pylorinegative patients, the mean excess d 13 CO 2 excretion at the 10-min, 20-min and 30-min sampling points was close to zero, indicating that 13 C-urea hydrolysis was minimal. Although this is not a head-to-head comparison, the mean excess d ively, using 50 mg of 13 C-urea powder. 11 Our data suggest that the 13 C-urea tablet confers protection against oropharyngeal urease activity and discriminates well between H. pylori-positive and H. pylorinegative cases. Two H. pylori-negative patients showed false positive breath test results at the 10-min and 30-min sampling points according to our cut-off value. The corresponding excess d 13 CO 2 excretion values at 10 min, 20 min and 30 min in the first patient were 1.3, 1.3 and 1.8, respectively, and in the second patient were 2.1, 1.6 and 1.4, respectively. Although there was no statistical difference between the three time points, our data suggest that the 20-min sampling point has the highest accuracy. However, to power the study to detect a difference between the three time points would require an enormous investigation, which is probably inappropriate within the context of this study.
Five patients had discordant results between rapid urease test and histology; they were all invited for a conventional 75-mg 13 C-UBT used in our laboratory. 6 There was total agreement between the 50-mg tabletbased 13 C-UBT and the conventional protocol, suggesting that the 50-mg tablet-based 13 C-UBT may be more accurate than the biopsy-based tests. The use of a test meal in 13 C-UBT is employed to increase the residence time of 13 C-urea in the stomach and to improve the contact between urease produced by H. pylori and the substrate. Citric acid has been suggested to be the best liquid test meal. 9, 10 The tablet formulation used in this study contains 456 mg of anhydrous citric acid. Although the dose of citrate is low when compared with that used in previous studies, the high accuracy obtained with the 50-mg 13 C-urea tablet suggests that low-dose citrate is equally efficacious. This tablet is well tolerated, and the 13 C-UBT can easily be performed outside the hospital ⁄ clinic, or even at home, after which a test-tube of expired air can be sent by regular mail for analysis. This may allow a potentially wider application of this non-invasive test for the diagnosis of H. pylori infection in regions at high risk of gastric cancer, such as China.
One of the limitations of this study is that we did not perform a head-to-head comparison of the 50-mg 13 C-urea tablet with 50 mg of 13 C-urea powder.
As mentioned previously, in order to detect a small difference in accuracy between the tablet and powder, an enormous investigation would be required, which may be impractical. In conclusion, we have shown that the 50-mg tabletbased 13 C-UBT (Diabact UBT), using a measurement interval of 20 min, is highly accurate for the diagnosis of H. pylori infection.
